Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer (ARASENS) (2022)

Peer-Reviewed Study · Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino A, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Mendez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators · March 24, 2022

Smith MR et al., 2022-03-24: ARASENS added darolutamide or placebo to androgen deprivation plus docetaxel in 1,306 men with metastatic hormone-sensitive prostate cancer. Overall survival at 4 years was 62.7% vs 50.4% (HR 0.68), with similar rates of grade 3-4 adverse events (66.1% vs 63.5%).

the risk of death was significantly lower, by 32.5%, in the darolutamide group than in the placebo group (hazard ratio 0.68; 95% confidence interval, 0.57 to 0.80; P<0.001).

Abstract (RESULTS)

Smith MR et al., 2022-03-24: ARASENS added darolutamide or placebo to androgen deprivation plus docetaxel in 1,306 men with metastatic hormone-sensitive prostate cancer. Overall survival at 4 years was 62.7% vs 50.4% (HR 0.68), with similar rates of grade 3-4 adverse events (66.1% vs 63.5%). Funder: 'Funded by Bayer and Orion Pharma'. Conflicts: NEJM disclosure forms referenced, not printed; several authors disclose Bayer/Orion roles in the full text. Maker: Bayer (Nubeqa/darolutamide) with Orion. Comparator: matching placebo on top of ADT plus docetaxel – i.e. docetaxel is the backbone in both arms, so this trial tests triplet therapy, not docetaxel itself. Study type: randomized trial.